Blockchain Registration Transaction Record

Sigyn's CardioDialysis™ Targets Heart Disease with Breakthrough Blood Purification Tech

Sigyn Therapeutics unveils CardioDialysis™, a blood purification device that treats cardiovascular disease using existing dialysis infrastructure. Targets multiple disease factors with 75-95% MACE reduction potential.

This development matters because cardiovascular disease remains the world's leading cause of death, and current drug therapies have significant limitations—particularly for vulnerable populations like end-stage renal disease patients who face 67% mortality from heart conditions. CardioDialysis™ represents a potential paradigm shift by addressing multiple disease factors simultaneously through existing dialysis infrastructure, offering hope where drugs have failed. For the millions of patients undergoing regular dialysis worldwide, this could mean extended survival and improved quality of life. More broadly, successful implementation could transform cardiovascular treatment approaches globally, potentially reducing major adverse events by 75-95% compared to statins' 25% average reduction, while creating substantial economic value through extended patient lifespans and reduced healthcare burdens.